Three muraceins, a family of muramyl peptides, were isolated from Nocardia orientalis as inhibitors of angiotensin-converting enzyme (ACE). Muracein A, the most potent inhibitor, inhibited ACE competitively with a Ki of 1.5 /LM. Liver alcohol dehydrogenase and carboxypeptidase A, two other zinc-containing enzymes, were not inhibited at 150 /IM. Inhibition of ACE could not be reversed by divalent cations. 
Preparation of ACE
ACE was prepared by suspending 10 g of rabbit lung acetone powder (Pel-Freez Biologicals) overnight in 120 ml of 50 mm phosphate buffer, pH 8.3 at 4°C. The suspension was homogenized in a blender for 3 minutes and centrifuged to remove solids (40,000 g for 1 hour at 4°C). The supernatant (110 ml) was then eluted from Sephadex G-75 (8 x 60 cm) with 50 mm Tris-HCl, pH 7.5. Column fractions were assayed for ACE hydrolytic activity.
Active fractions were pooled and used as the enzyme source for screening and kinetic studies.
Assays for ACE Activity Assays were performed spectrophotometrically by following hydrolysis of either furanacryloyl- NaCl, pH 7.5. Hydrolysis of FAPGG was monitored at 345 nm; NBGCG hydrolysis was followed at 475 nm.
Gilford spectrophotometers, either Model 250 or Model 203S, were used to measure hydrolysis rates for kinetic studies and 150 determinations.
Ki determinations were calculated using linear regression analyses of data plotted according to LINEWEAVER-BURK and DIXON12). Screening of fermentation broth supernatants was performed utilizing a Technicon Auto Analyzer II system. In this procedure, one volume of ACE was mixed with an equal volume of inhibitor (supernatant) before two volumes of 80 tcv NBGCG was added.
A reaction time of about 40 minutes was employed before final absorbances were recorded.
Captopril at 1.0 nM was used as a positive control throughout the assay. Effects of ACE inhibitors on smooth-muscle contraction were tested in excised guinea pig ileum using the method of RUBIN and collaborators"-").
Fermentation
Seed Cultures of N. orientalis SC 12,842 were prepared by transferring a loopful of surface growth from an agar slant into 500-m1 Erlenmeyer flasks containing 100 nil of the following medium: 0.40 yeast extract, 1.0% malt extract and 0.40% dextrose in distilled water. The pH was adjusted to 7.3 before sterilization. The flasks were then incubated at 25°C on a rotary shaker (300 rpm, 5-cm stroke) for approximately 72 hours.
A 3 % (v/v) transfer was made from the seed culture flasks to 500-ml Erlenmeyer flasks containing 100 ml each of the following: (NH,)2SO4 0.264%, K2HPO, 0.43%, KH2PO4 0.238%, MgSO4, • 7H~O 0.10% and trace salt solution 0.10 % (v/v) in distilled water. The salt solution contained CuSO4, 5H2O 0.64%, FeSO4, • 7H2O 0.11% MnCl2 • 4H2O 0.79% and ZnSO4, • 7H2O 0.15% in distilled water. The pH was adjusted to 6.8 7.0 before sterilization. At the time of inoculation 5.0 ml of sterile glucose (20%) was added to each flask. The flasks were then incubated at 25°C on a rotary shaker (300 rpm, 5-cm stroke) for approximately 120 hours. Inhibition of ACE activity was monitored using NBGCG as substrate in the auto analyzer assay. Occasional fermentations were allowed to proceed for 144 hours for maximum production of the muraceins.
At harvest the flask contents were pooled. After centrifugation, the resulting supernatant was used for the isolation of muraceins.
Biological Activity
ACE Inhibition
Muracein A and SQ 28,370 (reduction product of muracein A) inhibited ACE with 1,, values comparable to that observed for the snake venom peptide, teprotide (Table 2) . Muraceins B and C were considerably less potent inhibitors. Inhibition of ACE was not time-dependent when studied from I to 60 minutes. However, T;o values for the muraceins were lowered 20-30% if enzyme and inhibitor were preincubated briefly (less than one minute) before substrate was added to the reaction. This preincubation effect may reflect a slow equilibration of the enzyme-inhibitor complex. Muracein A behaved as a pure competitive inhibitor of ACE with a Ki value of 1.5 ;1M, as shown in Fig. 2 . A strong specificity for inhibition of ACE was exhibited by muracein A; at 150 fiM less than 5 % inhibition was observed with liver alcohol dehydrogenase and carboxypeptidase A, two other zinc-containing enzymes. Although a ligand may be formed between the zinc ion of ACE and carbonyl or carboxylate groups of the muraceins, strong chelation of divalent cations was not a characteristic of these inhibitors. This conclusion was also supported by the observation that inhibition of ACE by muracein A was not affected by the presence of 1.0 mm ZnCl2, CaCl2 or CoCl2.
When muracein A was tested for its effect on smooth-muscle contracting activity in the excised guinea pig ileum, the EC,* for AI antagonism was 64 gnu; the EC,, for bradykinin potentiation was * Effective concentration producing a 50% change in agonist effect . 
Discussion
The observed selectivity for ACE inhibition must involve specific interactions of muraceins with the enzyme active site. One representation of muracein binding to ACE is shown in Fig. 3 . For all the muraceins one can envision a ligand forming between the active site zinc and the carboxylate or carbonyl functionalities shown; however, this by itself could not account for the observed differential inhibition of ACE by the various muraceins.
The C, carboxylate of muracein A must be a critical functionality and may bind at the same site as the terminal carboxyl group of natural ACE substrates. Addition of alanylalanine at this position to give muracein B significantly increased the I,, value, suggesting a possible steric interference with binding. Because muracein A and SQ 28,370 inhibit ACE with comparable I50 values, the muramic acid moiety must not play a major role in determining affinity.
Taxonomic identification of Nocardia sp. is based in part upon the presence of diaminopimelic acid in cell wall hydrolysates. Thus, it is quite probable that the muraceins are fragments of Nocardia cell wall.
Other muramyl peptides have been described in the literature as molecules with a variety of biological activities.
A muramyl peptide isolated from human urine was reported to be a sleep-promoting facto15).
Muramyl peptides have also been noted for their immunomodulation activities, either as immunosuppressants or as immunostimulants16). For example, a liposome-encapsulated muramyl dipeptide analog was recently shown to protect mice against Candida albicans infection17).
However, the ACE inhibitory effects of muramyl peptides have not previously been reported.
Therefore, this specific inhibitory activity singles out the muraceins as novel biologically active muramyl peptides.
